A safe, proven, and effective therapy that consists of an implantable system that gently stimulates the sacral nerves to help restore* normal bladder and bowel function.1-7
An InterStim™ implant consists of an InterStim SureScan™ MRI lead and an InterStim™ implantable neurostimulator (INS). The InterStim SureScan™ MRI lead is placed parallel to the sacral nerve.
* Defined as a 50% or greater reduction in troublesome bladder or bowel symptoms.
Recharge-free neurostimulator for bladder and bowel control
The InterStim™ II system is the only recharge-free, long-term therapy that lets you get full-body† MRI scans.
† Under certain conditions; see approved labeling for details. Patients with InterStim™ SureScan™ MRI leads only.View InterStim™ system
The TYRX™ neuro absorbable antibacterial envelope is designed to provide device stabilization when implanted. The envelope also contains the antimicrobial agents rifampin and minocycline, which have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation.‡
‡ TYRX™ Neuro Absorbable Antibacterial Envelope Instructions for Use.Learn about TYRX™ neuro system
Take convenient courses specifically designed for clinicians treating patients with OAB, non-obstructive urinary retention, and chronic fecal incontinence.
Medical education, patient services, and clinical programs can help you deliver relief even more efficiently.
Bladder and bowel patient identification tools to help you improve patient access. Help your patients explore life without limits.
Have a representative contact you for more information about ASC therapies and procedures.
General customer service
For ordering assistance, call:
For technical or clinical product assistance:
The most common adverse events experienced during clinical studies include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
Medical necessity will dictate site of service for each individual patient. Physicians should confirm inpatient or outpatient admission criteria before selecting site of service.
Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268-2272.
Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromodulation. 2000;3(1):15-26.
Johnson M. Transcutaneous electrical nerve stimulation (TENS). In: Watson T. Electrotherapy: Evidence-Based Practice. 12th ed. Philadelphia, PA: Elsevier; 2008:259-286.
Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466-474.
Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. UrolClinNorthAm. 2005;32:11-18.
Blok BFM, Groen J, Bosch JLH, Veltman DJ, Lammertsma AA. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int. 2006;98(6):1238-1243.
Gourcerol G, Vitton V, Leroi AM, et al. How sacral nerve stimulation works in patients with faecalincontinence. Colorectal Dis. 2011;13(8):e203-11.